Physician profile
Charles A Brown
NPI 1982638557
$3,170.36
in general payments reported to CMS, 2019-2025
42 companies · $773 in 2025
The $773 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $342 · 2021: $451 · 2022: $418 · 2023: $525 · 2024: $376 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,674.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $362.36 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $304.58 | 2019-2025 | Repatha, Otezla, Repatha |
| Boston Scientific Corporation | $267.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $182.22 | 2020-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $181.50 | 2020-2025 | Wegovy, Ozempic |
| Janssen Pharmaceuticals, INC | $177.40 | 2020-2023 | Spravato |
| Medtronic, INC. | $164.91 | 2022-2023 | Micra |
| Gilead Sciences, INC. | $143.22 | 2025 | |
| Edwards Lifesciences Corporation | $135.14 | 2023 | |
| Merck Sharp & Dohme LLC | $127.04 | 2020-2023 | Verquvo, Belsomra, Steglatro |
| Biohaven Pharmaceuticals, INC. | $81.57 | 2020-2021 | |
| Esperion Therapeutics, INC. | $79.99 | 2024-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $74.71 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.54 | 2023-2024 | |
| Viiv Healthcare Company | $64.85 | 2024-2025 | Apretude |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.